4-苯并呋喃羧醛 | 95333-13-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 中文名称: 4-苯并呋喃羧醛
• 中文别名: 苯并呋喃-4-甲醛
• 英文名称: benzofuran-4-carbaldehyde
• 英文别名: benzofuran-4-carboxaldehyde；1-benzofuran-4-carbaldehyde
• CAS: 95333-13-4
• 化学式: C₉H₆O₂
• mdl: MFCD10699414
• 分子量: 146.145
• InChiKey: RLBNWXQWPDJHAT-UHFFFAOYSA-N

物化性质

• 沸点：
  251.5±13.0 °C(Predicted)
• 密度：
  1.238±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  30.2
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2932999099
• 储存条件：
  室温且干燥环境中保存

反应信息

• 作为反应物：
  描述：

  4-苯并呋喃羧醛 在 W-2 Raney Ni 盐酸 、 sodium hydroxide 、 氢气 、 sodium cyanoborohydride 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 四氢呋喃 、 乙醇 、 乙酸乙酯 、 异丙醇 为溶剂， 15.0 ℃ 、405.3 kPa 条件下， 生成 ethyl (2R,3S,4S)-4-(1-benzofuran-4-yl)-2-(4-methoxyphenyl)pyrrolidine-3-carboxylate
  参考文献：
  名称：

  Potent and Selective Non-Benzodioxole-Containing Endothelin-A Receptor Antagonists

  摘要：

  The benzodioxole ((methylenedioxy)benzene) group is present in a number of endothelin (ET) receptor antagonists thus far reported. As part of our own endothelin antagonist program we have developed (2R*,3R*,4S*)-1-(N,N-dibutylacetamido)-4-(1,3-benzodioxol-5-yl)-2-(4-methoxyphenyl)pyrrolidine-3-carboxylic acid acid (A-127722). This is a potent antagonist, binding to the ET(A) and ET(B) receptor subtypes with affinities (IC50) of 0.4 and 520 nM, respectively, and also contains the aforementioned benzodioxole. While this compound was seemingly optimized at its N-terminus, no effort had been directed toward understanding the contributions to binding affinity or receptor subtype selectivity conferred by the benzodioxole. Substitution by 1- or 2-naphthyl yielded weak antagonists. Oxygenated benzenes, such as p-anisyl, were potent compounds with IC(50)s in the low-nanomolar range. Simple deletion of either of the two oxygen atoms (dihydrobenzofurans) yielded extremely potent agents, possessing subnanomolar affinity for the ET(A) receptor. Additionally, the compounds showed enhanced selectivity, binding to the ET(B) receptor subtype in the micromolar range. This paper describes the development of this novel class of compounds.

  DOI：

  10.1021/jm960077r
• 作为产物：
  描述：

  benzofuran-4-carbonyl chloride 在 lithium aluminium tetrahydride 、 碳酸氢钠 作用下， 以 四氢呋喃 、 水 、 乙酸乙酯 为溶剂， 反应 1.75h， 生成 4-苯并呋喃羧醛
  参考文献：
  名称：

  BENZODIOXOLE, BENZOFURAN, DIHYDROBENZOFURAN, AND BENZODIOXANE MELATONERGIC AGENTS

  摘要：

  公开号：

  EP1027043B1

文献信息

• [EN] NEW THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] NOUVEAUX DÉRIVÉS DE THIÉNOPYRIMIDINE, PROCÉDÉ POUR LEUR PRÉPARATION ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
  申请人：SERVIER LAB

  公开号：WO2015097123A1

  公开（公告）日：2015-07-02

  Compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, R12, X, A and n are as defined in the description.

  式（I）的化合物：其中R1、R2、R3、R4、R5、R6、R7、R12、X、A和n的定义如描述中所述。
• Structure-Guided Design of EED Binders Allosterically Inhibiting the Epigenetic Polycomb Repressive Complex 2 (PRC2) Methyltransferase
  作者：Andreas Lingel、Martin Sendzik、Ying Huang、Michael D. Shultz、John Cantwell、Michael P. Dillon、Xingnian Fu、John Fuller、Tobias Gabriel、Justin Gu、Xiangqing Jiang、Ling Li、Fang Liang、Maureen McKenna、Wei Qi、Weijun Rao、Xijun Sheng、Wei Shu、James Sutton、Benjamin Taft、Long Wang、Jue Zeng、Hailong Zhang、Maya Zhang、Kehao Zhao、Mika Lindvall、Dirksen E. Bussiere

  DOI：10.1021/acs.jmedchem.6b01473

  日期：2017.1.12

  Inhibiting this activity by small molecules targeting EZH2 was shown to result in antitumor efficacy. Here, we describe the optimization of a chemical series representing a new class of PRC2 inhibitors which acts allosterically via the trimethyllysine pocket of the noncatalytic EED subunit. Deconstruction of a larger and complex screening hit to a simple fragment-sized molecule followed by structure-guided

  PRC2是一种多亚基甲基转移酶，参与早期胚胎发育和细胞生长的表观遗传调控。催化亚基EZH2主要使组蛋白H3的赖氨酸27甲基化，从而导致染色质紧实和肿瘤抑制基因的抑制。通过靶向EZH2的小分子抑制该活性可显示出抗肿瘤功效。在这里，我们描述了代表一类新的PRC2抑制剂的化学系列的优化，该类PRC2抑制剂通过非催化EED亚基的三甲基赖氨酸口袋发生变构作用。解构较大且复杂的筛选物会产生简单的片段大小的分子，然后进行结构引导的再生长和仔细的性质调节，以产生在功能测定和细胞活性中实现亚微摩尔抑制的化合物。
• MONOMERS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME
  申请人：Barany Francis

  公开号：US20140194383A1

  公开（公告）日：2014-07-10

  Described herein are monomers capable of forming a biologically useful multimer when in contact with one, two, three or more other monomers in an aqueous media. In one aspect, such monomers may be capable of binding to another monomer in an aqueous media (e.g. in vivo) to form a multimer, (e.g. a dimer). Contemplated monomers may include a ligand moiety, a linker element, and a connector element that joins the ligand moiety and the linker element. In an aqueous media, such contemplated monomers may join together via each linker element and may thus be capable of modulating one or more biomolecules substantially simultaneously, e.g., modulate two or more binding domains on a protein or on different proteins.

  本发明描述了在水中介质中与一个、两个、三个或更多其他单体接触时能够形成具有生物学用途的多聚体的单体。在一方面，这样的单体可能能够在水介质中（例如，体内）与另一个单体结合形成多聚体（例如，二聚体）。考虑的单体可能包括一个配体部分、一个连接元素和一个连接器元素，连接器元素连接配体部分和连接元素。在水介质中，这样的考虑单体可能通过每个连接元素相互连接，因此可能能够实质上同时调节一个或多个生物分子，例如，调节蛋白质上的两个或多个结合域，或者调节不同蛋白质上的结合域。
• TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF
  申请人：CHAN Ho Man

  公开号：US20160176882A1

  公开（公告）日：2016-06-23

  A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein R 1 , R 2 , R 3 , R 4 , R 5 , and n are as defined herein.

  提供了一种由化合物（I）或其药学上可接受的盐组成的药物，已被证明对治疗PRC2介导的疾病或紊乱有用：其中R1、R2、R3、R4、R5和n的定义如本文所述。
• [EN] IMIDAZOPYRIMIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER<br/>[FR] COMPOSÉS D'IMIDAZOPYRIMIDINE UTILES POUR LE TRAITEMENT DU CANCER
  申请人：NOVARTIS AG

  公开号：WO2017221100A1

  公开（公告）日：2017-12-28

  A compound of Formula (IA), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein A, R3, R4, R6, and R7 are as defined herein.

  提供了一种具有以下结构式（IA）的化合物，或其药用盐，已被证明对治疗PRC2介导的疾病或紊乱有用：其中A，R3，R4，R6和R7如本文所定义。